{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:09:39Z","timestamp":1782166179577,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s10238-014-0323-4","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T13:30:39Z","timestamp":1417527039000},"page":"433-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Metabolic syndrome and chronic arthritis: effects of anti-TNF-\u03b1 therapy"],"prefix":"10.1007","volume":"15","author":[{"given":"Nicola","family":"Maruotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"d\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,27]]},"reference":[{"issue":"Suppl 2","key":"323_CR1","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1186\/ar552","volume":"4","author":"JR Kalden","year":"2002","unstructured":"Kalden JR. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002;4(Suppl 2):S34\u201340.","journal-title":"Arthritis Res"},{"issue":"Suppl 2","key":"323_CR2","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1186\/ar1016","volume":"6","author":"AB Gottlieb","year":"2004","unstructured":"Gottlieb AB, Antoni CE. Treating psoriatic arthritis: how effective are TNF antagonists? Arthritis Res Ther. 2004;6(Suppl 2):S31\u20135.","journal-title":"Arthritis Res Ther"},{"key":"323_CR3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/aje\/152.10.908","volume":"152","author":"JB Meigs","year":"2000","unstructured":"Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol. 2000;152:908\u201311.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"323_CR4","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","volume":"28","author":"R Kahn","year":"2005","unstructured":"Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289\u2013304.","journal-title":"Diabetes Care"},{"issue":"25","key":"323_CR5","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program (NCEP)","year":"2002","unstructured":"National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143\u2013421.","journal-title":"Circulation"},{"issue":"4","key":"323_CR6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","volume":"24","author":"B Isomaa","year":"2001","unstructured":"Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683\u20139.","journal-title":"Diabetes Care"},{"issue":"11","key":"323_CR7","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.2337\/diacare.27.11.2676","volume":"27","author":"MP Stern","year":"2004","unstructured":"Stern MP, Williams K, Gonz\u00e1lez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and\/or cardiovascular disease? Diabetes Care. 2004;27(11):2676\u201381.","journal-title":"Diabetes Care"},{"key":"323_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-140-3-200402030-00007","volume":"140","author":"J Chen","year":"2004","unstructured":"Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167\u201374.","journal-title":"Ann Intern Med"},{"issue":"10","key":"323_CR9","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-143-10-200511150-00009","volume":"143","author":"M Hamaguchi","year":"2005","unstructured":"Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722\u20138.","journal-title":"Ann Intern Med"},{"issue":"4","key":"323_CR10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2265.1999.00701.x","volume":"50","author":"R Pasquali","year":"1999","unstructured":"Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf). 1999;50(4):517\u201327.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"323_CR11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1164\/ajrccm.165.5.2103001","volume":"165","author":"MS Ip","year":"2002","unstructured":"Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002;165(5):670\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"323_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/art.22466","volume":"57","author":"HK Choi","year":"2007","unstructured":"Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109\u201315.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"323_CR13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","volume":"48","author":"C Meune","year":"2009","unstructured":"Meune C, Touz\u00e9 E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50\u00a0years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2009;48(10):1309\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"323_CR14","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","volume":"59","author":"JA Avi\u00f1a-Zubieta","year":"2008","unstructured":"Avi\u00f1a-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690\u20137.","journal-title":"Arthritis Rheum"},{"key":"323_CR15","doi-asserted-by":"crossref","first-page":"147354","DOI":"10.1155\/2012\/147354","volume":"2012","author":"L Cavagna","year":"2012","unstructured":"Cavagna L, Boffini N, Cagnotto G, Inverardi F, Grosso V, Caporali R. Atherosclerosis and rheumatoid arthritis: more than a simple association. Mediat Inflamm. 2012;2012:147354.","journal-title":"Mediat Inflamm"},{"issue":"3","key":"323_CR16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/03009742.2011.626443","volume":"41","author":"VR Cunha da","year":"2012","unstructured":"da Cunha VR, Brenol CV, Brenol JC, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol. 2012;41(3):186\u201391.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"323_CR17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.atherosclerosis.2007.01.004","volume":"196","author":"CP Chung","year":"2008","unstructured":"Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196(2):756\u201363.","journal-title":"Atherosclerosis"},{"issue":"6","key":"323_CR18","doi-asserted-by":"crossref","first-page":"R218","DOI":"10.1186\/ar3203","volume":"12","author":"HH Dao","year":"2010","unstructured":"Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2010;12(6):R218.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"323_CR19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/met.2009.0124","volume":"8","author":"SK Raychaudhuri","year":"2010","unstructured":"Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331\u20134.","journal-title":"Metab Syndr Relat Disord"},{"issue":"4","key":"323_CR20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/acr.20364","volume":"63","author":"S Mathieu","year":"2011","unstructured":"Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(4):557\u201363.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"323_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/met.2013.0039","volume":"12","author":"S Pehlevan","year":"2014","unstructured":"Pehlevan S, Yetkin DO, Bahad\u0131r C, et al. Increased prevalence of metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2014;12(1):43\u20138.","journal-title":"Metab Syndr Relat Disord"},{"issue":"2","key":"323_CR22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/acr.20363","volume":"63","author":"CC Mok","year":"2011","unstructured":"Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195\u2013202.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"323_CR23","first-page":"714321","volume":"2012","author":"TY Zhu","year":"2012","unstructured":"Zhu TY, Li EK, Tam LS. Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol. 2012;2012:714321.","journal-title":"Int J Rheumatol"},{"key":"323_CR24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/ard.59.11.904","volume":"59","author":"SM Jones","year":"2000","unstructured":"Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis. 2000;59:904\u20139.","journal-title":"Ann Rheum Dis"},{"key":"323_CR25","first-page":"79","volume":"27","author":"F Oliviero","year":"2009","unstructured":"Oliviero F, Sfriso P, Baldo G, et al. Apolipoprotein A-I and cholesterol in synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Clin Exp Rheumatol. 2009;27:79\u201383.","journal-title":"Clin Exp Rheumatol"},{"key":"323_CR26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/CS20040326","volume":"109","author":"H Divecha","year":"2005","unstructured":"Divecha H, Sattar N, Rumley A, Cherry L, Lowe G, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond). 2005;109:171\u20136.","journal-title":"Clin Sci (Lond)"},{"key":"323_CR27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/MD.0b013e3181c10773","volume":"88","author":"C Gonzalez-Juanatey","year":"2009","unstructured":"Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 2009;88:358\u201365.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"323_CR28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","volume":"48","author":"C Popa","year":"2007","unstructured":"Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48(4):751\u201362.","journal-title":"J Lipid Res"},{"key":"323_CR29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0962-8924(01)02064-5","volume":"11","author":"V Baud","year":"2001","unstructured":"Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001;11:372\u20137.","journal-title":"Trends Cell Biol"},{"issue":"5091","key":"323_CR30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","volume":"259","author":"GS Hotamisligil","year":"1993","unstructured":"Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87\u201391.","journal-title":"Science"},{"issue":"44","key":"323_CR31","doi-asserted-by":"crossref","first-page":"15995","DOI":"10.1073\/pnas.0508122102","volume":"102","author":"LF Lee","year":"2005","unstructured":"Lee LF, Xu B, Michie SA, et al. The role of TNF-alpha in the pathogenesis of type 1 diabetes in the nonobese diabetic mouse: analysis of dendritic cell maturation. Proc Natl Acad Sci USA. 2005;102(44):15995\u20136000.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"323_CR32","doi-asserted-by":"crossref","first-page":"e33254","DOI":"10.1371\/journal.pone.0033254","volume":"7","author":"M Koulmanda","year":"2012","unstructured":"Koulmanda M, Bhasin M, Awdeh Z, et al. The role of TNF-\u03b1 in mice with type 1- and 2- diabetes. Plos One. 2012;7(5):e33254.","journal-title":"Plos One"},{"issue":"22","key":"323_CR33","doi-asserted-by":"crossref","first-page":"13018","DOI":"10.1074\/jbc.271.22.13018","volume":"271","author":"P Peraldi","year":"1996","unstructured":"Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996;271(22):13018\u201322.","journal-title":"J Biol Chem"},{"issue":"4","key":"323_CR34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2337\/diabetes.47.4.515","volume":"47","author":"LS Liu","year":"1998","unstructured":"Liu LS, Spelleken M, R\u00f6hrig K, Hauner H, Eckel J. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes. 1998;47(4):515\u201322.","journal-title":"Diabetes"},{"issue":"12","key":"323_CR35","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1210\/endo.139.12.6337","volume":"139","author":"KT Uysal","year":"1998","unstructured":"Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology. 1998;139(12):4832\u20138.","journal-title":"Endocrinology"},{"issue":"3","key":"323_CR36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2337\/diab.46.3.451","volume":"46","author":"GS Hotamisligil","year":"1997","unstructured":"Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 1997;46(3):451\u20135.","journal-title":"Diabetes"},{"issue":"1","key":"323_CR37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-5793(00)01250-3","volume":"469","author":"JK Sethi","year":"2000","unstructured":"Sethi JK, Xu H, Uysal KT, Wiesbrock SM, Scheja L, Hotamisligil GS. Characterisation of receptor-specific TNFalpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett. 2000;469(1):77\u201382.","journal-title":"FEBS Lett"},{"key":"323_CR38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1023\/A:1022346010304","volume":"22","author":"AD Blann","year":"1998","unstructured":"Blann AD, McCollum CN. Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation. 1998;22:483\u201391.","journal-title":"Inflammation"},{"issue":"5","key":"323_CR39","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1172\/JCI117936","volume":"95","author":"GS Hotamisligil","year":"1995","unstructured":"Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409\u201315.","journal-title":"J Clin Invest"},{"issue":"11","key":"323_CR40","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1073\/pnas.91.11.4854","volume":"91","author":"GS Hotamisligil","year":"1994","unstructured":"Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA. 1994;91(11):4854\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"323_CR41","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI118504","volume":"97","author":"M Saghizadeh","year":"1996","unstructured":"Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF-alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996;97:1111\u20136.","journal-title":"J Clin Invest"},{"key":"323_CR42","first-page":"E457","volume":"261","author":"T Poll van der","year":"1991","unstructured":"van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, Sauerwein HP. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol. 1991;261:E457\u201365.","journal-title":"Am J Physiol"},{"issue":"32","key":"323_CR43","doi-asserted-by":"crossref","first-page":"21839","DOI":"10.1016\/S0021-9258(18)54714-1","volume":"266","author":"JM Stephens","year":"1991","unstructured":"Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C\/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem. 1991;266(32):21839\u201345.","journal-title":"J Biol Chem"},{"issue":"11","key":"323_CR44","first-page":"1457","volume":"10","author":"B Zhang","year":"1996","unstructured":"Zhang B, Berger J, Hu E, et al. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol. 1996;10(11):1457\u201366.","journal-title":"Mol Endocrinol"},{"key":"323_CR45","doi-asserted-by":"crossref","first-page":"E527","DOI":"10.1152\/ajpendo.00110.2003","volume":"285","author":"JM Bruun","year":"2003","unstructured":"Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285:E527\u201333.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"323_CR46","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1161\/01.ATV.14.11.1866","volume":"14","author":"KR Feingold","year":"1994","unstructured":"Feingold KR, Marshall M, Gulli R, Moser AH, Grunfeld C. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb. 1994;14(11):1866\u201372.","journal-title":"Arterioscler Thromb"},{"key":"323_CR47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.physiol.62.1.413","volume":"62","author":"RS Ahima","year":"2000","unstructured":"Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413\u201337.","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"323_CR48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.180.3.995","volume":"180","author":"XD Yang","year":"1994","unstructured":"Yang XD, Tisch R, Singer SM, et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 1994;180(3):995\u20131004.","journal-title":"J Exp Med"},{"issue":"5","key":"323_CR49","first-page":"1045","volume":"74","author":"C Grunfeld","year":"1992","unstructured":"Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"323_CR50","first-page":"100","volume":"5","author":"L Lind","year":"1994","unstructured":"Lind L, Lithell H. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intensive Care. 1994;5:100\u20135.","journal-title":"Clin Intensive Care"},{"issue":"5 Suppl","key":"323_CR51","first-page":"595","volume":"11","author":"F Rossi Fanelli","year":"1995","unstructured":"Rossi Fanelli F, Cangiano C, Muscaritoli M, Conversano L, Torelli GF, Cascino A. Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition. 1995;11(5 Suppl):595\u2013600.","journal-title":"Nutrition"},{"key":"323_CR52","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"323_CR53","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.1988.6.2.344","volume":"6","author":"ML Sherman","year":"1988","unstructured":"Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E 3rd, Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988;6(2):344\u201350.","journal-title":"J Clin Oncol"},{"issue":"1","key":"323_CR54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000229685.37402.80","volume":"99","author":"A Picchi","year":"2006","unstructured":"Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99(1):69\u201377.","journal-title":"Circ Res"},{"issue":"1","key":"323_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5099\/aj100100001","volume":"2","author":"X Gao","year":"2010","unstructured":"Gao X, Picchi A, Zhang C. Upregulation of TNF-alpha and receptors contribute to endothelial dysfunction in zucker diabetic rats. Am J Biomed Sci. 2010;2(1):1\u201312.","journal-title":"Am J Biomed Sci"},{"key":"323_CR56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R. Atherosclerosis\u2014an inflammatory disease. N Engl J Med. 1999;340:115\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"323_CR57","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/euhj.2001.2805","volume":"23","author":"T Skoog","year":"2002","unstructured":"Skoog T, Dichtl W, Boquist S, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002;23(5):376\u201383.","journal-title":"Eur Heart J"},{"issue":"17","key":"323_CR58","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000037521.71373.44","volume":"106","author":"D H\u00fcrlimann","year":"2002","unstructured":"H\u00fcrlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106(17):2184\u20137.","journal-title":"Circulation"},{"key":"323_CR59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.20407","volume":"51","author":"C Gonzalez-Juanatey","year":"2004","unstructured":"Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in long-term anti-tumor necrosis-\u03b1 antibody-infliximab treated rheumatoid arthritis patients. Arthritis Rheum. 2004;51:447\u201350.","journal-title":"Arthritis Rheum"},{"key":"323_CR60","first-page":"83","volume":"24","author":"MA Gonzalez-Gay","year":"2006","unstructured":"Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"323_CR61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05287.x","volume":"1193","author":"MA Gonzalez-Gay","year":"2010","unstructured":"Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann NY Acad Sci. 2010;1193:153\u20139.","journal-title":"Ann NY Acad Sci"},{"key":"323_CR62","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/ard.2004.026534","volume":"64","author":"DN Kiortsis","year":"2005","unstructured":"Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64:765\u20136.","journal-title":"Ann Rheum Dis"},{"key":"323_CR63","first-page":"159","volume":"26","author":"B Seriolo","year":"2008","unstructured":"Seriolo B, Paolino S, Ferrone C, Cutolo M. Impact of long-term anti-TNFalpha treatment on insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:159\u201360.","journal-title":"Clin Exp Rheumatol"},{"key":"323_CR64","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10067-007-0539-8","volume":"26","author":"LS Tam","year":"2007","unstructured":"Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1495\u20138.","journal-title":"Clin Rheumatol"},{"key":"323_CR65","first-page":"1213","volume":"32","author":"LT Jacobsson","year":"2005","unstructured":"Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213\u20138.","journal-title":"J Rheumatol"},{"key":"323_CR66","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905\u201312.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"323_CR67","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3874","volume":"14","author":"I Stagakis","year":"2012","unstructured":"Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14(3):R141.","journal-title":"Arthritis Res Ther"},{"key":"323_CR68","first-page":"2440","volume":"33","author":"E Spanakis","year":"2006","unstructured":"Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006;33:2440\u20136.","journal-title":"J Rheumatol"},{"issue":"6","key":"323_CR69","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10067-013-2369-1","volume":"33","author":"L Costa","year":"2014","unstructured":"Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33(6):833\u20139.","journal-title":"Clin Rheumatol"},{"key":"323_CR70","first-page":"1004","volume":"114","author":"E Cauza","year":"2002","unstructured":"Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr. 2002;114:1004\u20137.","journal-title":"Wien Klin Wochenschr"},{"key":"323_CR71","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2133.2007.08188.x","volume":"157","author":"G Stinco","year":"2007","unstructured":"Stinco G, Piccirillo F, Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol. 2007;157:1273\u20134.","journal-title":"Br J Dermatol"},{"key":"323_CR72","first-page":"352686","volume":"2011","author":"KR Castro","year":"2011","unstructured":"Castro KR, Aikawa NE, Saad CG, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol. 2011;2011:352686.","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"323_CR73","first-page":"231","volume":"32","author":"F Genre","year":"2014","unstructured":"Genre F, L\u00f3pez-Mej\u00edas R, Miranda-Filloy JA, et al. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy. Clin Exp Rheumatol. 2014;32(2):231\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"323_CR74","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/annrheumdis-2013-204484","volume":"73","author":"F Genre","year":"2014","unstructured":"Genre F, L\u00f3pez-Mej\u00edas R, Miranda-Filloy JA, et al. Antitumour necrosis factor \u03b1 treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitispatients. Ann Rheum Dis. 2014;73(5):941\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"323_CR75","first-page":"850","volume":"30","author":"JA Miranda-Filloy","year":"2012","unstructured":"Miranda-Filloy JA, Llorca J, Carnero-L\u00f3pez B, Gonz\u00e1lez-Juanatey C, Blanco R, Gonz\u00e1lez-Gay MA. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin Exp Rheumatol. 2012;30(6):850\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"323_CR76","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/art.22447","volume":"56","author":"N Sattar","year":"2007","unstructured":"Sattar N, Crompton P, Cherry L, Kane D, Lowe G, McInnes IB. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo controlled study. Arthritis Rheum. 2007;56:831\u20139.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"323_CR77","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaut.2008.07.002","volume":"31","author":"F Ingegnoli","year":"2008","unstructured":"Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31(2):175\u20139.","journal-title":"J Autoimmun"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0323-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-014-0323-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0323-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T11:08:20Z","timestamp":1690715300000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-014-0323-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,27]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s10238-014-0323-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,27]]}}}